Alector management to participate in upcoming investor conferences.

Alector, a late-stage clinical biotechnology company, announced its participation in upcoming investor conferences, including Cantor Global Healthcare Conference 2025, Morgan Stanley 23rd Annual Global Healthcare Conference, and H.C. Wainwright 27th Annual Global Investment Conference. Management will participate in fireside chats and company presentations. Webcasts of the presentations will be available on Alector's website.

Alector Inc, a late-stage clinical biotechnology company, has announced its participation in several upcoming investor conferences. The company will be present at the Cantor Global Healthcare Conference 2025, Morgan Stanley 23rd Annual Global Healthcare Conference, and H.C. Wainwright 27th Annual Global Investment Conference. Management will engage in fireside chats and company presentations, providing investors with an opportunity to gain insights into the company's latest developments. Webcasts of these presentations will be available on Alector's official website.

Alector Inc is focused on developing therapies to counteract the progression of neurodegenerative diseases. The company's lead product, Latozinemab (AL001), is an investigational human recombinant monoclonal antibody designed to elevate progranulin (PGRN), a protein encoded by the granulin (GRN) gene that regulates lysosomal function, neuronal survival, and inflammation in the brain. Latozinemab is in Phase 3 clinical trials for the treatment of frontotemporal dementia with a granulin gene mutation (FTD-GRN), which is caused by heterozygous loss-of-function (LOF) mutations in the GRN gene and results in PGRN haploinsufficiency.

In addition to Latozinemab, Alector Inc is developing AL101/GSK4527226, which is in Phase 2 clinical trials. This product is designed to address the underlying causes of neurodegenerative diseases by targeting the GRN gene.

The participation in these conferences aligns with Alector Inc's strategy to increase visibility and engage with investors, analysts, and potential partners. The company aims to provide updates on its pipeline, clinical progress, and strategic initiatives.

For more information on Alector Inc's participation in these conferences, visit the company's official website.

References:

[1] Investing.com. (n.d.). Alector Inc. Retrieved July 02, 2025, from https://www.investing.com/equities/alector-inc